Equities researchers at Guggenheim began coverage on shares of Cellectis (NASDAQ:CLLS) in a research report issued to clients and investors on Friday, March 16th, MarketBeat reports. The firm set a “neutral” rating on the biotechnology company’s stock.
Several other research analysts have also recently weighed in on CLLS. BidaskClub cut Cellectis from a “strong-buy” rating to a “buy” rating in a report on Wednesday, March 14th. Nomura lifted their price target on shares of Cellectis to $73.00 and gave the company a “buy” rating in a research report on Wednesday, March 14th. ValuEngine raised Cellectis from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Zacks Investment Research lowered Cellectis from a “buy” rating to a “hold” rating in a research report on Thursday, November 16th. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $40.00 price objective on shares of Cellectis in a research report on Thursday, December 28th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $42.67.
Shares of CLLS stock opened at $28.83 on Friday. The firm has a market capitalization of $1,035.80, a P/E ratio of -10.37 and a beta of 1.86. Cellectis has a 1 year low of $21.25 and a 1 year high of $38.85.
Cellectis (NASDAQ:CLLS) last released its quarterly earnings data on Monday, March 12th. The biotechnology company reported ($0.76) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.64) by ($0.12). Cellectis had a negative net margin of 298.01% and a negative return on equity of 35.63%. The company had revenue of $6.91 million for the quarter, compared to analysts’ expectations of $10.10 million. analysts forecast that Cellectis will post -2.62 earnings per share for the current fiscal year.
Large investors have recently made changes to their positions in the company. Perceptive Advisors LLC purchased a new position in Cellectis during the fourth quarter worth about $10,203,000. BlackRock Inc. purchased a new position in Cellectis during the fourth quarter worth about $4,422,000. Sphera Funds Management LTD. raised its holdings in Cellectis by 71.1% during the third quarter. Sphera Funds Management LTD. now owns 348,736 shares of the biotechnology company’s stock worth $9,922,000 after purchasing an additional 144,972 shares in the last quarter. Bain Capital Public Equity Management LLC purchased a new position in Cellectis in the fourth quarter valued at about $2,848,000. Finally, Millennium Management LLC increased its holdings in Cellectis by 1,356.2% in the fourth quarter. Millennium Management LLC now owns 104,290 shares of the biotechnology company’s stock valued at $3,040,000 after buying an additional 97,128 shares in the last quarter. 20.31% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “Cellectis (NASDAQ:CLLS) Earns Neutral Rating from Analysts at Guggenheim” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/04/09/cellectis-clls-receives-new-coverage-from-analysts-at-guggenheim.html.
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.